(2S,3R,4R,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-2-[(2S,3R,4R,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4R,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-2-[(2S,3R,4R,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol
• 化学式: C₂₈H₃₀F₂N₆O₈S
• 分子量: 648.6
• InChiKey: YGIDGBAHDZEYMT-AXXYRMHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  227
• 氢给体数：
  6
• 氢受体数：
  15

文献信息

• [EN] GALACTOSIDE INHIBITORS FOR THE TREATMENT OF ALPHA-SYNUCLEINOPTHIES<br/>[FR] INHIBITEURS GALACTOSIDES POUR LE TRAITEMENT DES ALPHA-SYNUCLÉINOPATHIES
  申请人：GALECTO BIOTECH AB

  公开号：WO2015155207A1

  公开（公告）日：2015-10-15

  The present invention relates to a pharmaceutical composition for use in a method for treatment or prevention of a-synucleinopathies wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain. The invention also concerns a method for treatment or prevention of a-synucleinopathies in a mammalian subject, the method comprising administering a therapeutically effective amount of at least one composition to the subject, wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain.

  本发明涉及一种药物组合物，用于治疗或预防α-突触核蛋白病，其中该组合物包括一种用于在哺乳动物大脑中调节半乳糖凝集素活性的分子。该发明还涉及一种治疗或预防哺乳动物主体中α-突触核蛋白病的方法，该方法包括向主体中注射至少一种组合物的治疗有效量，其中该组合物包括一种用于在哺乳动物大脑中调节半乳糖凝集素活性的分子。
• Novel Galactoside Inhibitor of Galectins
  申请人：Galecto Biotech AB

  公开号：US20140121179A1

  公开（公告）日：2014-05-01

  The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.

  本发明涉及一种通式（I）的化合物：化合物（I）适用于治疗哺乳动物的肺纤维化，例如特发性肺纤维化。此外，本发明涉及一种监测人体主体肺纤维化发展或进展的方法，一种监测或预测肺纤维化患者症状恶化的方法，以及一种治疗肺纤维化的方法，例如对于具有提示肺纤维化或症状恶化的galectin-3水平的人类主体的特发性肺纤维化。
• Novel galactoside inhibitor of galectins
  申请人：GALECTO BIOTECH AB

  公开号：US20160096861A1

  公开（公告）日：2016-04-07

  Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

  提供的是通式（I）的化合物：公式（I）的化合物适用于治疗哺乳动物的肺纤维化，如特发性肺纤维化。还提供了一种治疗肺纤维化的方法，例如对于人类患有表明肺纤维化或症状加剧的半乳糖凝集素-3水平的特发性肺纤维化患者，以及制备该化合物的方法。
• Galactoside Inhibitor of Galectin-3 and its use for Treating Pulmonary Fibrosis
  申请人：GALECTO BIOTECH AB

  公开号：US20150274764A1

  公开（公告）日：2015-10-01

  The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

  本发明涉及一种适用于肺部给药的通式(I)化合物。通式(I)的化合物适用于治疗哺乳动物的肺纤维化，例如特发性肺纤维化。此外，本发明还涉及一种用于治疗肺纤维化的方法，例如用于治疗人体主体的特发性肺纤维化。
• GALACTOSIDE INHIBITORS FOR THE TREATMENT OF ALPHA-SYNUCLEINOPTHIES
  申请人：Galecto Biotech AB

  公开号：EP3129032A1

  公开（公告）日：2017-02-15